FIELD: medicine.
SUBSTANCE: invention concerns medicine, particularly neurology and methods of Alzheimer's disease treatment. It involves administration of memantine or its pharmaceutically acceptable salt in starting amount of 5 mg per day with dosage increase by 5 mg per day each week till it reaches 20 mg per day.
EFFECT: monotherapy method allowing for efficient treatment of Alzheimer's disease cases of low to moderate severity, which were previously treated by acetylcholinesterase inhibitor, in particular.
10 cl, 3 tbl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF LOW-VOLUME PLASMAPHERESIS FOR THE TREATMENT OF EARLY AND MIDDLE STAGES OF ALZHEIMER'S DISEASE | 2019 |
|
RU2802628C2 |
| METHODS FOR COGNITIVE FUNCTION SUPPORT, TREATMENT OR IMPROVEMENT | 2013 |
|
RU2635522C2 |
| DRUG FOR PREVENTION OR TREATMENT OF TAUPATHY | 2018 |
|
RU2739199C1 |
| DRUG FOR PREVENTION OR TREATMENT OF BRAIN ATROPHY | 2018 |
|
RU2759727C2 |
| COMBINATION OF 5-HT-RECEPTOR ANTAGONIST AND ACETYLCHOLINESTERASE INHIBITOR FOR USE IN TREATMENT OF ALZHEIMER'S DISEASE IN SUBPOPULATION OF PATIENTS THAT ARE CARRIERS OF ApoE4 ALLELES | 2018 |
|
RU2776366C2 |
| AGENT AND METHOD FOR PREVENTION AND TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE | 2008 |
|
RU2384343C2 |
| METHODS OF TREATING ALZHEIMER'S DISEASE | 2015 |
|
RU2720468C2 |
| METHODS FOR TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS | 2013 |
|
RU2675786C2 |
| METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 2018 |
|
RU2789485C2 |
| COMBINATION OF COMPONENTS FOR PREVENTION AND TREATMENT OF INDISPOSITION | 2011 |
|
RU2646830C2 |
